Wan-Young Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wan-Young Kim has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Chul Woo Yang
Division of Nephrology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
1 shared publication - Euijung Park
Epithelial Systems Biology Laboratory, Systems Biology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
1 shared publication - Eun-Jeong Kwon
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
1 shared publication - Eunyoung Park
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
1 shared publication Gu-Kwan Jeong
Division of Science Education, Chonbuk National University, Chonju 561-756, South Korea
1 shared publication- Hong Seok Choi
Department of Biochemistry and Cell Biology Kyungpook National University Taegu Korea
1 shared publication
Latest Publications
- Open Access
- 1 July 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (4) , 612-625
Evaluation of the novel ALK5 inhibitor EW-7197 on therapeutic efficacy in renal fibrosis using a three-dimensional chip model
Background: EW-7197, a potent oral ALK5 inhibitor, was assessed for its impact on transforming growth factor beta 1 (TGF-β1)–induced fibrosis in a three-dimensional (3D) renal fibrosis-on-a-chip and a mouse model. The evaluation included tubular epithelial- mesenchymal transition, angiogenesis, and inflammatory cytokine expression. Methods: In a 3D renal fibrosis-on-a-chip model, three cell types(kidney fibroblasts, human proximal tubular cells, and human umbilical vein endothelial cells) were cultured and treated with TGF-β1 and EW-7197. Alpha smooth muscle actin (α-SMA) and keratin 8 (KRT-8) was assessed, angiogenesis observed via confocal microscopy, and cytokine levels measured by polymerase chain reaction, immunoassay, and enzyme-linked immunosorbent assay. In a cisplatin-induced renal fibrosis mouse model, blood urea nitrogen levels, TGF-β, and Smad 2/3 were determined, and fibrosis was assessed with Masson’s trichrome stain. Results: The α-SMA expression was significantly lower in the EW-7197 group than in the TGF-β fibrosis group. TGF-β decreased the expression of the epithelial marker KRT-8, an effect that was reversed by EW-7197 and SB431542. In the TGF-β–induced fibrosis model, the length of the thick vessels was reduced, and the diameter of both thick and thin vessels was decreased, but EW-7197 reversed these effects. EW-7197 significantly reduced the messenger RNA expression of TGF-β and increased the levels of vascular endothelial growth factor receptor 2, interleukin (IL)-10, and IL-6. EW-7197 reduced the levels of secretory cytokines TGF-β1, TGF-β3, IL- 1β. In the cisplatin-induced renal fibrosis mouse model, EW-7197 reduced renal fibrosis by down-regulating TGF-β signaling. Conclusion: EW-7197 attenuated the TGF-β1–induced fibrotic cellular response in the 3D chip model and animal model. These findings indicate the potential effect of EW-7197 in attenuating renal fibrosis.
- 1 July 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (4) , 612-625
Open AccessEvaluation of the novel ALK5 inhibitor EW-7197 on therapeutic efficacy in renal fibrosis using a three-dimensional chip model
Background: EW-7197, a potent oral ALK5 inhibitor, was assessed for its impact on transforming growth factor beta 1 (TGF-β1)–induced fibrosis in a three-dimensional (3D) renal fibrosis-on-a-chip and a mouse model. The evaluation included tubular epithelial- mesenchymal transition, angiogenesis, and inflammatory cytokine expression. Methods: In a 3D renal fibrosis-on-a-chip model, three cell types(kidney fibroblasts, human proximal tubular cells, and human umbilical vein endothelial cells) were cultured and treated with TGF-β1 and EW-7197. Alpha smooth muscle actin (α-SMA) and keratin 8 (KRT-8) was assessed, angiogenesis observed via confocal microscopy, and cytokine levels measured by polymerase chain reaction, immunoassay, and enzyme-linked immunosorbent assay. In a cisplatin-induced renal fibrosis mouse model, blood urea nitrogen levels, TGF-β, and Smad 2/3 were determined, and fibrosis was assessed with Masson’s trichrome stain. Results: The α-SMA expression was significantly lower in the EW-7197 group than in the TGF-β fibrosis group. TGF-β decreased the expression of the epithelial marker KRT-8, an effect that was reversed by EW-7197 and SB431542. In the TGF-β–induced fibrosis model, the length of the thick vessels was reduced, and the diameter of both thick and thin vessels was decreased, but EW-7197 reversed these effects. EW-7197 significantly reduced the messenger RNA expression of TGF-β and increased the levels of vascular endothelial growth factor receptor 2, interleukin (IL)-10, and IL-6. EW-7197 reduced the levels of secretory cytokines TGF-β1, TGF-β3, IL- 1β. In the cisplatin-induced renal fibrosis mouse model, EW-7197 reduced renal fibrosis by down-regulating TGF-β signaling. Conclusion: EW-7197 attenuated the TGF-β1–induced fibrotic cellular response in the 3D chip model and animal model. These findings indicate the potential effect of EW-7197 in attenuating renal fibrosis.
- Open Access
- 26 June 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (13) , e70771
Vasopressin‐Sensitive Aqp2 Regulation Mediated by the TAZ ‐ NR4A1 Axis in Renal Collecting Duct Cells
Regulation of aquaporin‐2 ( Aqp2 ) gene is essential for body water homeostasis. This study investigated how TAZ (a transcriptional coactivator with PDZ‐binding motif, Wwtr1 ) controls vasopressin‐driven AQP2 expression. AQP2 expression was studied using collecting duct‐specific TAZ‐knockout (TAZ f/f ; HoxB7Cre) mice and siRNA‐mediated knockdown of TAZ in vasopressin‐responsive mpkCCDc11 cells. Downstream factors of TAZ were identified using transcriptomics and bioinformatics. The TAZ f/f ; HoxB7Cre mice demonstrated polyuria and a significant decrease in AQP2 abundance in the kidney cortex and the outer medulla. dDAVP treatment (10 −9 M, 24 h) on mpkCCDc11 cells significantly increased AQP2 mRNA and protein levels. However, siRNA‐mediated TAZ knockdown (TAZ‐KD) markedly attenuated these effects without affecting cAMP levels. Immunocytochemical analysis revealed a substantial decrease in AQP2 immunolabeling intensity in TAZ‐KD cells following dDAVP stimulation. RNA sequencing analysis identified 1370 and 1985 differentially expressed genes in TAZ‐KD cells under basal conditions and after dDAVP treatment, respectively. Among 17 previously identified transcription factor (TF) candidates, seven ( Nr4a1, Cebpb, Mef2d, Elf3, Klf5, Junb, Stat3 ) were significantly upregulated by dDAVP in either control or TAZ‐KD conditions. Among them, RT‐qPCR analysis identified Nr4a1 as a TAZ‐dependent TF, and immunoblotting revealed reduced NR4A1 protein levels in TAZ‐KD cells upon dDAVP stimulation. This finding suggests its role as a TAZ‐regulated target in dDAVP response pathway. Accordingly, Nr4a1‐KD reduced the dDAVP‐induced upregulation of Aqp2 mRNA and protein. KEGG pathway enrichment analysis revealed that HIF‐1 signaling and glycolysis as central pathways affected by TAZ. TAZ‐NR4A1 axis acts as a novel transcriptional regulatory mechanism in controlling vasopressin‐mediated AQP2 expression.
- 26 June 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (13) , e70771
Open AccessVasopressin‐Sensitive Aqp2 Regulation Mediated by the TAZ ‐ NR4A1 Axis in Renal Collecting Duct Cells
Regulation of aquaporin‐2 ( Aqp2 ) gene is essential for body water homeostasis. This study investigated how TAZ (a transcriptional coactivator with PDZ‐binding motif, Wwtr1 ) controls vasopressin‐driven AQP2 expression. AQP2 expression was studied using collecting duct‐specific TAZ‐knockout (TAZ f/f ; HoxB7Cre) mice and siRNA‐mediated knockdown of TAZ in vasopressin‐responsive mpkCCDc11 cells. Downstream factors of TAZ were identified using transcriptomics and bioinformatics. The TAZ f/f ; HoxB7Cre mice demonstrated polyuria and a significant decrease in AQP2 abundance in the kidney cortex and the outer medulla. dDAVP treatment (10 −9 M, 24 h) on mpkCCDc11 cells significantly increased AQP2 mRNA and protein levels. However, siRNA‐mediated TAZ knockdown (TAZ‐KD) markedly attenuated these effects without affecting cAMP levels. Immunocytochemical analysis revealed a substantial decrease in AQP2 immunolabeling intensity in TAZ‐KD cells following dDAVP stimulation. RNA sequencing analysis identified 1370 and 1985 differentially expressed genes in TAZ‐KD cells under basal conditions and after dDAVP treatment, respectively. Among 17 previously identified transcription factor (TF) candidates, seven ( Nr4a1, Cebpb, Mef2d, Elf3, Klf5, Junb, Stat3 ) were significantly upregulated by dDAVP in either control or TAZ‐KD conditions. Among them, RT‐qPCR analysis identified Nr4a1 as a TAZ‐dependent TF, and immunoblotting revealed reduced NR4A1 protein levels in TAZ‐KD cells upon dDAVP stimulation. This finding suggests its role as a TAZ‐regulated target in dDAVP response pathway. Accordingly, Nr4a1‐KD reduced the dDAVP‐induced upregulation of Aqp2 mRNA and protein. KEGG pathway enrichment analysis revealed that HIF‐1 signaling and glycolysis as central pathways affected by TAZ. TAZ‐NR4A1 axis acts as a novel transcriptional regulatory mechanism in controlling vasopressin‐mediated AQP2 expression.
- 1 January 2010
- Vol. 25 (1) , 33-44
Expression of OAT1 and OAT3 in differentiating proximal tubules of the mouse kidney.
Organic anion transporter 1 (OAT1) and OAT3 in the proximal tubules (PT) of the kidney play important roles in the elimination of harmful endogenous compounds and xenobiotics from the body. We investigated the temporal and spatial expression of OAT1 and OAT3 in the differentiating PT in mouse kidney. Ontogenic expression of OAT1 and OAT3 was investigated by immunohistochemical analysis. The S1, S2, and S3 segments of the PT were identified using antibodies to aquaporin 1 (AQP1), Na+-HCO3- cotransporter 1 (kNBC1), and AQP4. OAT1 immunoreactivity was first detected at PT in the inner cortex of 15-day-old fetuses (F15) and in the outer cortex of 7-day old pups. OAT3 was first observed in the distal tubule of F14 and in S2 segment of the PT of F16 and in S1 and S3 segments around the time of birth; expression increased through postpartum day 21. The ontogenic pattern of expression of OAT1 and OAT3 in the differentiating PT suggests that both transporters may function in the S2 segment in the fetus, but not until after birth in S1 and S3 segments.
- 1 January 2010
- Vol. 25 (1) , 33-44
Expression of OAT1 and OAT3 in differentiating proximal tubules of the mouse kidney.
Organic anion transporter 1 (OAT1) and OAT3 in the proximal tubules (PT) of the kidney play important roles in the elimination of harmful endogenous compounds and xenobiotics from the body. We investigated the temporal and spatial expression of OAT1 and OAT3 in the differentiating PT in mouse kidney. Ontogenic expression of OAT1 and OAT3 was investigated by immunohistochemical analysis. The S1, S2, and S3 segments of the PT were identified using antibodies to aquaporin 1 (AQP1), Na+-HCO3- cotransporter 1 (kNBC1), and AQP4. OAT1 immunoreactivity was first detected at PT in the inner cortex of 15-day-old fetuses (F15) and in the outer cortex of 7-day old pups. OAT3 was first observed in the distal tubule of F14 and in S2 segment of the PT of F16 and in S1 and S3 segments around the time of birth; expression increased through postpartum day 21. The ontogenic pattern of expression of OAT1 and OAT3 in the differentiating PT suggests that both transporters may function in the S2 segment in the fetus, but not until after birth in S1 and S3 segments.
- 1 March 2005
- Published by Elsevier in Colloids and Surfaces A: Physicochemical and Engineering Aspects
- Vol. 255 (1-3) , 79-83
Synthesis of nano-sized polypyrrole-coated polystyrene latexes
- 1 March 2005
- Published by Elsevier in Colloids and Surfaces A: Physicochemical and Engineering Aspects
- Vol. 255 (1-3) , 79-83
Synthesis of nano-sized polypyrrole-coated polystyrene latexes